Press release archive
Browse GSK's global press release archive for media and investors. Search by keyword or browse by year/business category.
Press releases issued by our local operating companies can be viewed on our market websites.
-
Results announcement for the first quarter 2012
Sales growth of +2% CER Further R&D delivery, operational leverage returns to shareholders. Core EPS 27.3p (+7%), dividend up 6% to 17p
-
GlaxoSmithKline reaches agreement to divest non-core over-the-counter (OTC) brands in international markets for £164 million
GSK announced it's reached agreement to divest non-core OTC brands in its international markets to Aspen for 163;164 million in cash.
-
GSK confirms offer to acquire Human Genome Sciences for US$13.00 per share in cash
GSK confirms it made an offer to the Board of Directors of HGS on 11/04 proposing to acquire all of the outstanding shares for US$13.00
-
GSK provides update on corporate responsibility commitments in 2011 report
GSK published its Corporate Responsibility Report, reiterating commitments to operate responsibly & transparently
-
GSK receives further data from phase lll studies of albiglutide in type 2 diabetes
GSK today announced that topline results have been received from seven of the eight Harmony Phase III studies investigating albiglutide.
-
Shionogi-ViiV Healthcare announces initial data from pivotal phase III study of dolutegravir in HIV
SPRING-2 study meets primary endpoint of non-inferiority of dolutegravir compared to raltegravir over 48 weeks in treatment of HIV patients.
-
GlaxoSmithKline to increase its ownership in Theravance
GSK will acquire, 10,000,000 shares of Theravance common stock at a price of $21.2887 per share, for a total investment of $212,887,000.
-
GSK and Theravance announce completion of the Relovair™* registrational programme and topline results from Relovair™ vs. Advair® phase III studies in COPD
GSK & THNX announced study results for Relovair in patients with COPD evaluating the efficacy compared to placebo in treatment of asthma
-
GSK confirms significant investments in UK manufacturing: Ulverston in Cumbria selected as site of new biopharmaceutical factory
GSK today confirmed it will invest over 163m in the UK manufacturing sites to increase production of pharmaceutical products & vaccines
-
GSK announces positive vote from FDA panel for pazopanib in certain advanced soft tissue sarcomas
GSK announced the ODAC voted 11:2 in support a favourable benefit; risk assessment for use of Votrient in patients with soft tissue sarcoma.
-
GlaxoSmithKline provides further update on divestment of non-core over-the-counter (OTC) brands
GSK announced intention to divest Consumer Healthcare OTC products predominantly in the US & EU with aggregate sales of approx 163million.
-
GSK reinforces commitment to youth training with launch of new UK apprenticeship programme
GSK announced launch of a new apprenticeship scheme. The programme will sit alongside GSK's established schemes & is aimed at 16-24yo
-
Regulatory Update: GSK announces submissions for two influenza vaccines
GSK announced today that it has submitted regulatory files for two of its influenza vaccines currently in development.
-
Innovative UK research project to study the value medicines bring to patients in the real world
Unique collaboration to ensure medicines under development meet patient and healthcare system needs.
-
GSK and Daiichi Sankyo vaccines joint venture to become largest vaccines company in Japan
GSK announced that it has signed an agreement with Daiichi Sankyo Co., Ltd. to form JV expected to create #1 vaccines company in Japan.
-
GlaxoSmithKline receives positive opinion in Europe from the CHMP for Nimenrix®
GSK announced that EMA's CHMP is recommending marketing authorisation for Nimenrix for immunisation against meningococcal disease
-
EU and US Regulatory Update – Tykerb/Tyverb® (lapatinib)
GSK announced it has submitted regulatory applications in EU & US related to Tykerb/ Tyverb (lapatinib) to treat metastatic breast cancer.
-
GSK results announcement for Q4 and full year 2011
GSK delivers continued underlying sales growth*, R&D progress and improving financial returns to shareholders
-
GSK joins new global partnership to help defeat ten neglected tropical diseases by 2020
GSK announced it has joined other global pharma companies and organisations in a united effort to defeat neglected tropical diseases.
-
GSK announces changes to the Board
GSK announced at annual GM in 2013,that Sir Crispin Davis, Sir Robert Wilson and Mr Larry Culp will not stand for re-election to the Board.
